NORDEA INVESTMENT MANAGEMENT AB
Position in ARQT — Arcutis Biotherapeutics, Inc.
CIK 1218210
STOCKHOLM, V7
Position in ARQT
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$4,545,194
-$1,310,372 QoQ
Shares Held
192,920
-4.3% QoQ
Ownership
0.154%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in ARQT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026NORDEA INVESTMENT MANAGEMENT AB holds $224,709,274 across 23 Biotechnology names. ARQT ranks #13 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
94,322 | $72,876,949 | |
| 2 | RPRX |
Royalty Pharma plc
|
788,022 | $37,801,414 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
306,439 | $19,213,724 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
27,171 | $12,132,937 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
50,936 | $10,169,371 | |
| 6 | EXEL |
Exelixis, Inc.
|
201,553 | $8,644,607 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
113,902 | $6,434,323 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
51,821 | $5,461,932 |
All Filings in ARQT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,545,194 | 192,920 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $5,855,566 | 201,638 | Shares | Defined | 2026-01-08 | |
| No filing history on record for this holder in this stock. | ||||||